Researcher
Paul Cos
- Research Expertise:In vitro and in vivo biofilm assays, Integrated antimicrobial (bacteria, fungi, yeasts and parasites) screening and profiling of pure compounds and extracts, targeting redox homeostasis in mycobacteria
- Keywords:MICROBIOLOGY, BACTERIOLOGY, BIOFILMS, INFLAMMATION, Pharmacy and pharmacology
- Disciplines:Microbiology, Systems biology, Laboratory medicine
- Research techniques:In vitro and in vivo (pre-clinical) models of infectious diseases (bacteria and fungi), evaluation of drugs
- Users of research expertise:Pharmaceutical companies (big pharma, SME, spin-off), news agencies, journalists, government agencies, regulatory (EU) agencies, non-governmental organisations in the field of infectious diseases
Affiliations
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Member
From1 Oct 2006 → 30 Sep 2020
Projects
1 - 10 of 59
- SEP BOF 2022 - DelNAM PlusFrom1 Dec 2022 → TodayFunding: BOF - projects
- Prevention of ventilator-associated pneumonia: analysis of the in vitro and in vivo anti-biofilm capacity of cecropin-based coatings on endotracheal tubes.From1 Nov 2022 → TodayFunding: FWO fellowships
- Chemical probes for imaging bacterial proteases in lung infections.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- Respiratory co-infection models for fundamental and translational biomedical research.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- Infrastructure for Diverse Applications of Single Cell Sorting and Dispensing using Microfluidics.From1 Jun 2022 → TodayFunding: BOF - scientific equipment program
- Implementation of in vivo models to identify potential candidates for treatment of Dry Eye DiseaseFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - projects
- Persistence in Streptococcus pneumoniae infections: elucidation of the importance of persister cells in chronic and recurrent infectionsFrom1 Nov 2020 → TodayFunding: FWO fellowships
- In vivo evaluation of biofilm-related pneumonia.From1 Oct 2020 → 30 Sep 2021Funding: BOF - projects
- Springboard for excellence in advanced development of antibacterials (SPRINGBOARD).From1 Sep 2020 → TodayFunding: H2020-EU.4. - Spreading excellence and widening participation
- 3D printing of drug loaded medical devices for personalized medicine.From1 May 2020 → 30 Apr 2022Funding: IOF - technology concept exploration
Publications
1 - 10 of 272
- In vitro modelling of bacterial pneumonia(2024)
Authors: Laure Mahieu, Laurence Van Moll, Linda De Vooght, Peter Delputte, Paul Cos
Pages: 1 - 23 - A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors(2024)
Authors: Natalia Smiejkowska, Lauren Oorts, Linda De Vooght, Rob Geens, Henri-Philippe Mattelaer, Koen Augustyns, Sergei V. Strelkov, Dirk Lamprecht, Koen Temmerman, Yann Sterckx, et al.
Pages: 1 - 22 - Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infections(2024)
Authors: Linda De Vooght, Y. Gansemans, F. Van Nieuwerburgh, Paul Cos
Pages: 1 - 14 - All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?(2024)
Authors: Lotte Jacobs, Kim Stobbelaar, Paul Cos, Peter Delputte
Pages: 1 - 27 - Bioinsecticide potential of ethanol extracts from Persea americana (Lauraceae) seeds on Aedes aegypti mosquitoes(2023)
Authors: Silvia Molina Bertrán, Idelsy Chil-Nunez, Julio Cesar Escalona-Arranz, Raimundo Nonato Picanco-Souto, Alejandro Felipe Gonzalez, Jesus Garcia Diaz, Paul Cos, Gabriel Llauradó Maury, Humberto Joaquin Morris-Quevedo
Pages: 404 - 414 - Selected strategies to fight pathogenic bacteria(2023)
Authors: Aiva Plotniece, Arkadij Sobolev, Claudiu T. Supuran, Fabrizio Carta, Fredrik Björkling, Henrik Franzyk, Jari Yli-Kauhaluoma, Koen Augustyns, Paul Cos, Linda De Vooght, et al.
Pages: 1 - 27 - In vitro persistence level reflects In vivo antibiotic survival of natural Pseudomonas aeruginosa isolates in a murine lung infection model(2023)
Authors: Laure Verstraete, Juliana Aizawa Porto de Abreu, Matthias Govaerts, Linda De Vooght, Rob Lavigne, Jan Michiels, Bram van den Bergh, Paul Cos
Pages: 1 - 17 - Development and validation of a multiplex electrochemiluminescence immunoassay to evaluate dry eye disease in rat tear fluids(2023)
Authors: Agnese Compagnone, Linda De Vooght, Paul Cos
Pages: 1 - 15 - Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents(2023)
Authors: Charlotte Courtens, Frits van Charante, Thibaut Quennesson, Martijn Risseeuw, Paul Cos, Guy Caljon, Tom Coenye, Serge Van Calenbergh
Pages: 1 - 14 - In-depth biological characterization of two black soldier fly anti- Pseudomonas peptides reveals LPS-binding and immunomodulating effects(2023)
Authors: Laurence Van Moll, Milan Wouters, Jeroen De Smet, Linda De Vooght, Peter Delputte, Mik Van Der Borght, Paul Cos
Pages: 1 - 15
Patents
1 - 5 of 5
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
Linked dataset
1 - 1 of 1